Quotes

Back To Menu

Alkem Laboratories Ltd NSE  /  BSE

Pharmaceuticals, Mid Cap

Invest

27 Jan 2023 | 04:14 PM

3,000.70
-19.50 (-0.65%)

Independent Research

theScreeners

We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts negative since 21-Apr-2020

    Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 21-Apr-2020 at a price of 2581.70.

  • Valuation Rating

    Fairly priced

    Based on its growth potential and our own criteria, at its current price the stock is fairly valued.

  • MT Tech Trend

    Trend positive since 10-Apr-2020

    The forty day Medium Term Technical Trend is positive since 10-Apr-2020. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 2504.643.

  • 4W REL Performance

    Under pressure (vs. SENSEX30)

    The four week relative underperformance versus SENSEX30 is -4.780.

Risk parameters

  • Risk Zone

    Low

    The stock has been on the low-sensitivity level since 21-May-2019.

  • Bear Market

    Below average sensitivity to market corrections

    On average, the stock has a tendency to minimize the drops in the index by -143%.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 254%.

  • Beta

    46 Low sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 46%.

  • Correlation

    0.44 Fair correlation to SENSEX30

    0.4382% of stock movements are explained by index variations.

  • Value at Risk

    Rs.260.71 The medium term value at risk is estimated at 260.71 or 0.10030%

    The value at risk is estimated at 260.71. The risk is therefore 0.10030%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    17.61 Current year to 2022 annualized estimate

    The annualized growth estimate is for the current year to 2022.

  • P/E Ratio

    20.65 Estimated PE for 2022

    The estimated PE is for the year 2022.

  • G/PE Ratio

    0.89 0.749% premium to expected growth

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential: 0.749% premium.

  • Dividend Yield

    0.85% Dividend is largely covered by profits

    The twelve month estimated dividend yield represents 17.454% of earnings forecasts.

  • Global Evaluation

    Slightly positive

    The stock is classified in the slightly positive zone since 14-Feb-2020.